ASCO 2014 Coverage
In patients with triple-negative breast cancer (TNBC) who are BRCA1/2 mutation carriers, pathologic complete response (pCR) is not a surrogate for relapse-free survival, in contrast to those with non-BRCA mutations.
Immediately integrating cancer treatment and palliative care might improve survival at 1 year in patients with advanced cancers, suggest findings from the ENABLE III randomized controlled trial, presented at the 2014 ASCO Annual Meeting.
Family members caring for patients with advanced cancer benefit from early initiation of phone-based training and support.
In patients with breast cancer who had previously received monthly intravenous bisphosphonate therapy for bone metastases for a year or longer, maintenance zoledronic acid administered every 12 weeks was noninferior to every 4 weeks.
Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.
Adult and young adult cancer survivors face cognitive and sexual late effects from cancer and its treatment, according to data compiled from an online cancer survivorship care planning tool presented at the 2014 ASCO Annual Meeting.
Patients with locally advanced nasopharyngeal cancer (NPC) do not benefit from the addition of neoadjuvant gemcitabine, carboplatin, and paclitaxel (GCP) to cisplatin chemoradiation.
Upfront standard androgen deprivation therapy plus six cycles of docetaxel significantly improves overall survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.
Baseline hypertension and BMI can affect worsening hypertension among patients administered vascular endothelial growth factor signaling pathway inhibitors, according to research presented at the 2014 ASCO Annual Meeting.
For the approximately 60,000 men in the United States with prostate cancer who are asymptomatic after radical primary treatment yet have a PSA relapse, it's safe to postpone androgen deprivation therapy, a study presented at the 2014 American Society of Clinical Oncology Annual Meeting concluded.
Sign Up for Free e-newsletters
- Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
- Myelofibrosis: From Diagnosis to Early Intervention
- FDA Approves HPV Vaccine for People Through Age 45
- HPV Vaccination and Anti-programmed Cell Death 1 Inhibition Improve Survival in Patients With Invasive HPV-16
- Anxiety, Depression in Prostate Cancer: Managing Psychosocial Effects in Male Patients
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Tool Addresses Well-being of Informal Caregivers of Patients With Cancer
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Strength and Hope for Women in the Mist of Cancer
- Prospective Study Measures Cognitive, Treatment Effects in Older Breast Cancer Survivors
- Immune Checkpoint Inhibitor Therapy May Affect Thyroid Function
- Hypofractionated Radiotherapy After Conservative Surgery May Increase Low-intermediate Grade Late Fibrosis in Breast Cancer Patients
- Should Increased Breast Density Dictate More Breast Cancer Screenings?
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|